[68Ga]Ga-HER2 Affibody PET/CT与MRI早期预测乳腺癌新辅助靶向治疗反应的比较
该研究纳入45例HER2阳性乳腺癌患者,在基线及新辅助治疗(NAT)两周期后行[68Ga]Ga-HER2 Affibody PET/CT与MRI,评估ΔSUVmax%等参数预测病理完全缓解(pCR)的价值。45例中27例(60%)达pCR;联合PET模型LOOCV AUC为0.887(95%CI:0.781-0.969),显著高于联合MRI模型的0.642(95%CI:0.474-0.803,p=0.015)。
要点
- ΔSUVmax%是有前景的pCR早期预测指标。
- 联合PET模型预测pCR优于基于MRI的联合模型。
- PET模型在10%-90%阈值概率下临床净获益更高。
核心结论
- ΔSUVmax%是有前景的pCR早期预测指标,[68Ga]Ga-HER2 Affibody PET/CT联合模型预测价值优于MRI模型,有望作为指导个体化治疗决策的生物标志物。
研究设计与样本
- 单中心研究,45例HER2阳性乳腺癌患者均在基线及NAT两周期后行[68Ga]Ga-HER2 Affibody PET/CT与MRI检查。
- 采用单变量logistic回归筛选与pCR相关的参数,评估多重共线性后构建联合PET模型(ΔSUVmax%、TBR2)与联合MRI模型(ADC2、ΔADC%)。
- 模型性能采用留一交叉验证(LOOCV)评估,并行ROC曲线、校准曲线与决策曲线分析。
主要发现
- 45例中27例(60%)达到pCR。
- 治疗后pCR组PET/CT参数显著更低、ΔSUVmax%显著更高,MRI来源的ADC与ΔADC%值显著更高。
- 联合PET模型LOOCV AUC为0.887(95%CI:0.781-0.969),显著高于联合MRI模型的0.642(95%CI:0.474-0.803,p=0.015)。
- 校准方面PET模型(p=0.404)数值上优于MRI模型(p=0.309)。
- 决策曲线分析显示PET模型在10%-90%阈值概率范围内临床净获益更高。
关键数值与推荐
- 45例中27例(60%)达到pCR。
- 联合PET模型LOOCV AUC为0.887(95%CI:0.781-0.969)。
- 联合MRI模型LOOCV AUC为0.642(95%CI:0.474-0.803),PET与MRI模型AUC比较p=0.015。
- 校准p值:PET模型p=0.404,MRI模型p=0.309。
- 决策曲线分析阈值概率范围10%-90%。
临床怎么用
- 对HER2阳性乳腺癌NAT患者,可在基线及两周期后行[68Ga]Ga-HER2 Affibody PET/CT,以ΔSUVmax%联合TBR2构建模型早期预测pCR。
- 该联合PET模型预测效能优于MRI联合模型,可辅助个体化治疗决策。
- 解读预测结果时需结合校准与决策曲线信息,评估不同阈值下的临床净获益。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate early ΔSUVmax% for predicting pathological complete response (pCR) in HER2-positive breast cancer patients undergoing neoadjuvant therapy (NAT), to build a combined [68Ga]Ga-HER2 Affibody PET/CT model, and to compare its performance with magnetic resonance imaging (MRI). METHODS: 45 patients underwent both [68Ga]Ga-HER2 Affibody PET/CT and MRI at baseline and after two cycles of NAT. Univariate logistic regression identified parameters associated with pCR. After assessing multicollinearity, combined PET (ΔSUVmax%, TBR2) and MRI (ADC2,ΔADC%) models were constructed. The model performance was evaluated using leave-one-out cross-validation (LOOCV) method. Receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis were performed. RESULTS: 27 of the 45 enrolled patients achieved pCR (60%). After treatment, the pCR group showed significantly lower PET/CT parameters, a significantly higher ΔSUVmax%, and significantly higher MRI-derived ADC and ΔADC% values compared to the non-pCR group. The combined PET model showed a LOOCV AUC of 0.887 (95% CI: 0.781-0.969), significantly higher than that of the combined MRI model (0.642, 95% CI: 0.474-0.803, p = 0.015). Calibration was numerically better for the PET model (p = 0.404) than for the MRI model (p = 0.309), indicating a relative advantage for PET. Decision curve analysis indicated higher clinical net benefit for the PET model across threshold probabilities of 10%-90%. CONCLUSION: ΔSUVmax% is a promising early predictor of pCR.The [68Ga]Ga-HER2 Affibody PET/CT combined model provides superior predictive value compared with MRI‑based model and could serve as a promising biomarker to guide personalized treatment decisions.
引用
- An R, Sun Y, Yang R, et al. Comparison of [68Ga]Ga-HER2 Affibody PET/CT and MRI for the early prediction of response to targeted neoadjuvant therapy in breast cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42209818. doi:10.1007/s00259-026-07920-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。